Norrbacka相关文献与解析，生知库 | 链接生命科学的每一步

Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease

非肽类恶唑基脯氨酰寡肽酶配体对 α-突触核蛋白帕金森病小鼠模型具有改善疾病的作用

doi:10.1021/acs.jmedchem.3c00235

Tommi P Kilpeläinen, Henri T Pätsi, Reinis Svarcbahs, Ulrika H Julku, Tony S Eteläinen, Hengjing Cui, Samuli Auno, Nina Sipari, Susanna Norrbacka, Teppo O Leino, Maria Jäntti, Timo T Myöhänen, Erik A A Wallén

Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy

脯氨酰寡肽酶充当分子伴侣介导的自噬与巨自噬之间的纽带

期刊:Biochemical Pharmacology

影响因子:5.3

doi:10.1016/j.bcp.2021.114899

H Cui, S Norrbacka, T T Myöhänen

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes

评估治疗对2型糖尿病患者生活质量的影响：与治疗相关属性的效用值文献综述

期刊:Patient-Related Outcome Measures

影响因子:1.8

doi:10.2147/PROM.S322390

Valentine, William; Norrbacka, Kirsi; Boye, Kristina Secnik

Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy

脯氨酰寡肽酶抑制可减少多系统萎缩细胞模型中的 α-突触核蛋白聚集

期刊:Journal of Cellular and Molecular Medicine

影响因子:4.3

doi:10.1111/jcmm.16910

Hengjing Cui, Tommi Kilpeläinen, Lydia Zouzoula, Samuli Auno, Kalevi Trontti, Sampo Kurvonen, Susanna Norrbacka, Iiris Hovatta, Poul Henning Jensen, Timo T Myöhänen

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

与口服和注射用GLP-1受体激动剂治疗2型糖尿病相关的健康状态效用

期刊:Quality of Life Research

影响因子:2.7

doi:10.1007/s11136-021-02808-2

Matza, Louis S; Cutts, Katelyn N; Stewart, Katie D; Norrbacka, Kirsi; García-Pérez, Luis-Emilio; Boye, Kristina S

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain

胰高血糖素样肽-1受体激动剂治疗2型糖尿病：来自西班牙一项真实世界研究的数据

期刊:Diabetes Therapy

影响因子:2.6

doi:10.1007/s13300-021-01039-5

Norrbacka, Kirsi; Sicras-Mainar, Antoni; Lebrec, Jeremie; Artime, Esther; Díaz, Silvia; Tofé-Povedano, Santiago; Hernández, Ignacio; Romera, Irene

Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis

法国2型糖尿病患者GLP-1受体激动剂治疗模式及持续性：一项回顾性队列分析

期刊:Diabetes Therapy

影响因子:2.6

doi:10.1007/s13300-021-01055-5

Zimner Rapuch, Sarah; Divino, Victoria; Norrbacka, Kirsi; Boye, Kristina; Lebrec, Jeremie; Rosilio, Myriam; DeKoven, Mitch; Guerci, Bruno

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics

一项关于度拉糖肽和利拉鲁肽治疗2型糖尿病患者健康结局的真实世界观察性前瞻性研究（TROPHIES）：设计和基线特征

期刊:Diabetes Therapy

影响因子:2.6

doi:10.1007/s13300-021-01076-0

García-Pérez, Luis-Emilio; Boye, Kristina S; Rosilio, Myriam; Jung, Heike; Heitmann, Elke; Norrbacka, Kirsi; Federici, Marco Orsini; Gentilella, Raffaella; Guerci, Bruno; Giorgino, Francesco; Aigner, Ulrich; Sapin, Hélène

Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A

脯氨酰寡肽酶抑制通过蛋白磷酸酶 2A 激活自噬

期刊:Pharmacological Research

影响因子:9.1

doi:10.1016/j.phrs.2019.104558

Reinis Svarcbahs, Maria Jäntti, Tommi Kilpeläinen, Ulrika H Julku, Lauri Urvas, Saara Kivioja, Susanna Norrbacka, Timo T Myöhänen

Utilities for Complications Associated with Type 2 Diabetes: A Review of the Literature

2型糖尿病并发症的实用指南：文献综述

Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease

非肽类恶唑基脯氨酰寡肽酶配体对 α-突触核蛋白帕金森病小鼠模型具有改善疾病的作用

Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy

脯氨酰寡肽酶充当分子伴侣介导的自噬与巨自噬之间的纽带

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes

评估治疗对2型糖尿病患者生活质量的影响：与治疗相关属性的效用值文献综述

Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy

脯氨酰寡肽酶抑制可减少多系统萎缩细胞模型中的 α-突触核蛋白聚集

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

与口服和注射用GLP-1受体激动剂治疗2型糖尿病相关的健康状态效用

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain

胰高血糖素样肽-1受体激动剂治疗2型糖尿病：来自西班牙一项真实世界研究的数据

Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis

法国2型糖尿病患者GLP-1受体激动剂治疗模式及持续性：一项回顾性队列分析

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics

一项关于度拉糖肽和利拉鲁肽治疗2型糖尿病患者健康结局的真实世界观察性前瞻性研究（TROPHIES）：设计和基线特征

Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A

脯氨酰寡肽酶抑制通过蛋白磷酸酶 2A 激活自噬